ScholarLens Back to search
1969•PEDIATRICSRequires access

EVALUATION OF VINCRISTINE SULFATE AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR METASTATIC NEUROBLASTOMA

Margaret P. Sullivan, Audrey H. Nora, Panja Kulapongs, Daniel M. Lane, Joan Windmiller, William G. Thurman

Open publisher page 25 citations

Abstract

Among 18 evaluated children with metastatic neuroblastoma who were treated with vincristine sulfate by the Pediatric Division, Southwest Cancer Chemotherapy Study Group, the overall response rate was only 28%. A cyclic regimen using vincristine sulfate and cyclophosphamide alternately weekly produced a response rate of 38% among 21 children. The median duration of remission in each of the treatment groups was 3 months. Previous reports of a high degree of effectiveness for the cyclic regimen could not be confirmed. The presence of definite antitumor effect, however, should encourage the further exploration of the potential of chemotherapeutic regimens as adjuvants to surgery and radiation and as prophylactic therapy for children in whom the disease has not yet become metastatic.

About this research paper

What this paper is about

Among 18 evaluated children with metastatic neuroblastoma who were treated with vincristine sulfate by the Pediatric Division, Southwest Cancer Chemotherapy Study Group, the overall response rate was only 28%. A cyclic regimen using vincristine sulfate and cyclophosphamide alternately weekly produced a response rate of 38% among 21 children. The median duration of remission in each of the treatment groups was 3 months. Previous reports of a high degree of effectiveness for the cyclic regimen could not be confirmed. The presence of definite antitumor effect, however, should encourage the further exploration of the potential of chemotherapeutic regimens as adjuvants to surgery and radiation and as prophylactic therapy for children in whom the disease has not yet become metastatic.

Why it matters

OpenAlex reports 25 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Among 18 evaluated children with metastatic neuroblastoma who were treated with vincristine sulfate by the Pediatric Division, Southwest Cancer Chemotherapy Study Group, the overall response rate was only 28%. A cyclic regimen using vincristine sulfate and cyclophosphamide alternately weekly produced a response rate of 38% among 21 children. The median duration of remission in each of the treatment groups was 3 months. Previous reports of a high degree of effectiveness for the cyclic regimen could not be confirmed. The presence of definite antitumor effect, however, should encourage the further exploration of the potential of chemotherapeutic regimens as adjuvants to surgery and radiation and as prophylactic therapy for children in whom the disease has not yet become metastatic.

Key concepts: Medicine, Vincristine, Cyclophosphamide, Regimen, Chemotherapy, Neuroblastoma, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
EVALUATION OF VINCRISTINE SULFATE AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR METASTATIC NEUROBLASTOMA — Research Paper | ScholarLens